Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Profound Medical (PROF) EBITDA Margin (2024 - 2025)

Profound Medical (PROF) has 2 years of EBITDA Margin data on record, last reported at 126.24% in Q4 2025.

  • For Q4 2025, EBITDA Margin rose 2859.0% year-over-year to 126.24%; the TTM value through Dec 2025 reached 250.26%, up 3662.0%, while the annual FY2025 figure was 250.26%, 3662.0% up from the prior year.
  • EBITDA Margin reached 126.24% in Q4 2025 per PROF's latest filing, up from 166.1% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 126.24% in Q4 2025 and bottomed at 619.69% in Q1 2024.